Abbott Laboratories (ABT)

73.92
1.04 1.43
NYSE
Prev Close 72.88
Open 73.64
Day Low/High 72.75 / 74.90
52 Wk Low/High 56.81 / 77.33
Volume 9.71M
Exchange NYSE
Shares Outstanding 1756.47B
Market Cap 128.01B
Div & Yield N.A. (N.A)

Latest News

Exiting Our Danaher Position for a Big Gain

We are ringing the register this afternoon and declaring victory on DHR ahead of earnings.

Video: Jim's Daily Rundown for Wednesday

Jim discusses Abbott Laboratories' earnings release, his view of the Apple-Qualcomm settlement as it relates to the 5G cycle, several upcoming earnings reports, Anadarko Petroleum, UnitedHealth and much more!

Jim Cramer's Takeaway From Abbott's Earnings

Jim Cramer's Takeaway From Abbott's Earnings

Jim Cramer breaks down what he was watching when Abbott reported earnings Wednesday morning.

Abbott Labs Tops Expectations With First-Quarter Results

This was a very good quarter and the stock performance today is more of a reflection of the hatred for anything healthcare related as well as ABT's already premium valuation.

Abbott Laboratories Reports Healthy First-Quarter Profit

Abbott Laboratories Reports Healthy First-Quarter Profit

Abbott reports earnings above its own guidance and that of Wall Street analysts.

Jim Cramer's Thoughts on Abbott and Netflix Earnings, Qualcomm and Apple

Jim Cramer's Thoughts on Abbott and Netflix Earnings, Qualcomm and Apple

Qualcomm and Apple have settled their disputes, and Abbott and Netflix both released earnings.

Jim Cramer Breaks Down Qualcomm, Netflix, and Abbott

Jim Cramer Breaks Down Qualcomm, Netflix, and Abbott

Jim Cramer weighs in on Abbott's earnings, Qualcomm's dispute with Apple is over and Netflix's earnings.

Abbott Reports First-Quarter 2019 Results

Abbott Reports First-Quarter 2019 Results

- Sales and EPS growth exceed guidance; projects strong full-year outlook

Good News From China, Plus Netflix Earnings and Playing CSX: Market Recon

Good News From China, Plus Netflix Earnings and Playing CSX: Market Recon

China reported positive data, bolstering markets. Netflix had a beat on earnings, but faces fierce competition ahead. CSX is a thing of beauty.

Qualcomm and Apple, Sprint and T-Mobile, Netflix - 5 Things You Must Know

Qualcomm and Apple, Sprint and T-Mobile, Netflix - 5 Things You Must Know

U.S. stock futures rise Wednesday, following on from Tuesday's gains that were spurred on by generally solid earnings reports; Qualcomm surges after the chipmaker ends its long-running dispute with Apple; Netflix's second-quarter forecast disappoints Wall Street; Sprint and T-Mobile slide after a report says their proposed merger is getting resistance form the Justice Department.

WATCH: Buy Stocks in Companies That Run Their Earnings Calls Well, Says Cramer

WATCH: Buy Stocks in Companies That Run Their Earnings Calls Well, Says Cramer

They usually run their businesses well, too, Cramer says in revealing his '5 Rules for Trading Stocks During Earnings Season.'

What We Are Watching With This Week's Earnings

UnitedHealth Group and Johnson & Johnson report Tuesday, Abbott Labs on Wednesday, and Honeywell, Schlumberger and Danaher on Thursday.

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.

Weekly Roundup

Stocks grind higher as earnings season kicks indexes into gear.

Abbott And The Abbott Fund Support Relief Efforts For Cyclone Idai

Abbott And The Abbott Fund Support Relief Efforts For Cyclone Idai

Funding, rapid diagnostics to address emerging threats of cholera, malaria and other diseases, meet key relief needs in Southeast Africa

Weekly Roundup

Markets pushed higher as we gear up for first-quarter results starting next week.

Weekly Roundup

Markets move higher as investors shrug off slowing growth to focus on U.S.-China Trade Deal hopes.

Markets Lower Wednesday but We Have Been Raising Cash

We have long cautioned on our member-only conference calls about the flush of IPOs coming to market and its impact to stocks.

Weekly Roundup

Stocks finish week sharply lower on worries over global economic growth slowing after earlier surging on Fed's more accommodating stance.

Markets Open Lower Friday, a Check on CVS Health After Last Night's Interview

We are encouraged with CVS Health's plans to fix what has hurt the company and we reiterate that the stock is still inexpensive.

Trimming Abbott Labs Before the Closing Bell

As much as we continue to believe in the company and its strong organic growth trends, discipline calls for us to lock in some of our big gains.

Abbott Hosts Conference Call For First-Quarter Earnings

Abbott Hosts Conference Call For First-Quarter Earnings

ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019, before the market opens.

Abbott Announces CE Mark For Alinity™ M Diagnostics System And Assays, The Latest In Molecular Technology, To Help Deliver Critical Test Results And Benefits To Patients

Abbott Announces CE Mark For Alinity™ M Diagnostics System And Assays, The Latest In Molecular Technology, To Help Deliver Critical Test Results And Benefits To Patients

- Alinity m will allow labs to meet the growing demand for infectious disease testing by offering increased efficiency and market-leading speed and accuracy

New Data For Abbott's HeartMate 3™ Highlights Unparalleled Performance Of Industry's Leading Heart Pump

New Data For Abbott's HeartMate 3™ Highlights Unparalleled Performance Of Industry's Leading Heart Pump

- New MOMENTUM 3 data show the best outcomes seen in a randomized controlled clinical trial for left ventricular assist device (LVAD) therapy

New Late-Breaking Analyses From Landmark COAPT™ Trial Show Benefits Of Abbott's MitraClip™ Device

New Late-Breaking Analyses From Landmark COAPT™ Trial Show Benefits Of Abbott's MitraClip™ Device

- New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy

Weekly Roundup

Strong earnings boost shares in a rebound week for stocks.

Updates on 4 Portfolio Names

These stocks are moving on recent headlines.

Abbott Receives FDA Approval For Expanded Indication For MitraClip™ Device

Abbott Receives FDA Approval For Expanded Indication For MitraClip™ Device

- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation

TheStreet Quant Rating: B (Buy)